6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents

Details 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents

2007-10-23

2007-10-23

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S281000

Reexamination Certificate

active

10950542

ABSTRACT:
This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.

REFERENCES:
patent: 5593996 (1997-01-01), Pees et al.
patent: 5612345 (1997-03-01), Becher et al.
patent: 5750766 (1998-05-01), Krummel et al.
patent: 5756509 (1998-05-01), Pees
patent: 5808066 (1998-09-01), Krummel et al.
patent: 5817663 (1998-10-01), Pees et al.
patent: 5854252 (1998-12-01), Pees et al.
patent: 5948783 (1999-09-01), Pees et al.
patent: 5955252 (1999-09-01), Goto et al.
patent: 5965561 (1999-10-01), Pees et al.
patent: 5981534 (1999-11-01), Pfrengle
patent: 5985883 (1999-11-01), Pees
patent: 5986135 (1999-11-01), Pfrengle et al.
patent: 5994360 (1999-11-01), Pfrengle
patent: 6020338 (2000-02-01), Pfrengle et al.
patent: 6117865 (2000-09-01), Pees
patent: 6117876 (2000-09-01), Pees et al.
patent: 6124301 (2000-09-01), Aven et al.
patent: 6156925 (2000-12-01), Meyer et al.
patent: 6204269 (2001-03-01), Pfrengle et al.
patent: 6242451 (2001-06-01), Pees
patent: 6255309 (2001-07-01), Pees et al.
patent: 6268371 (2001-07-01), Sieverding et al.
patent: 6277856 (2001-08-01), Cotter et al.
patent: 6284762 (2001-09-01), Pfrengle
patent: 6297251 (2001-10-01), Pees et al.
patent: 6387848 (2002-05-01), Aven et al.
patent: 2002/0045631 (2002-04-01), Aven et al.
patent: 2002/0061882 (2002-05-01), Pees et al.
patent: 2003/0055069 (2003-03-01), Pees et al.
patent: 0 550 113 (1993-07-01), None
patent: 0 562 615 (1993-09-01), None
patent: 0 770 615 (1997-05-01), None
patent: 0 782 997 (1997-07-01), None
patent: 0 550 113 (1997-10-01), None
patent: 0 834 513 (1998-04-01), None
patent: 0 562 615 (1998-06-01), None
patent: 0 945 453 (1999-09-01), None
patent: 0 989 130 (2000-03-01), None
patent: 0 988 790 (2003-05-01), None
patent: 0 943 241 (2003-06-01), None
patent: 1 431 299 (2004-06-01), None
patent: 2 784 381 (2000-04-01), None
patent: 2001/43978 (2001-02-01), None
patent: 2001/43978 (2001-02-01), None
patent: WO94/20501 (1994-09-01), None
patent: WO98/41496 (1998-09-01), None
patent: WO98/46607 (1998-10-01), None
patent: WO98/46608 (1998-10-01), None
patent: WO99/41255 (1999-08-01), None
patent: WO99/48893 (1999-09-01), None
patent: WO 00/18227 (2000-04-01), None
patent: WO 01/35738 (2001-05-01), None
patent: WO 02/46195 (2002-06-01), None
patent: WO 02/067679 (2002-09-01), None
patent: WO 02/02563 (2002-10-01), None
patent: WO 02/083676 (2002-10-01), None
patent: WO 03/022850 (2003-03-01), None
patent: WO 03/089433 (2003-10-01), None
M.C. Wani, et al.; J. Am. Chem. Soc.; vol. 93; pp. 2325-2327; 1971.
Ravindra Pratap Rao, et al.; J. Het.Chem.; pp. 1021-1023; 1973.
Ganapathi R. Revankar, et. al.; Journal of Medicinal Chemistry; vol. 18; No. 12; pp. 1253-1255; 1975.
Schiff, et al.; Nature; vol. 277; pp. 665-667; 1979.
Nirbhay Kumar; J. Biol. Chem.; vol. 256; No. 20; pp. 10435-10441; 1981.
E. Hamel, et al.; J. Biol. Chem.; vol. 259; No. 4; pp. 2501-2508; 1984.
Ding-Wu Shen, et al.; J. Biol. Chem., vol. 261, No. 17; pp. 7762-7770; 1986.
Tim McGrath and Melvin S. Center; Biochem. Biophys. Res. Commun.; vol. 145; No. 3; pp. 1171-1176; 1987.
William P. McGuire, et al.; Ann. Int. Med.; vol. III; pp. 273-279; 1989.
Lori J. Goldstein, et al.; J. Natl. Cancer Inst. (Bethesda); vol. 81; pp. 116-124; 1989.
Eric K. Rowinsky, et al.; J. Natl. Cancer Inst.; vol. 82; No. 15; pp. 1247-1259; 1990.
Philip Skehan, et al.; J. Natl. Cancer Inst.; vol. 82; No. 13; pp. 1107-1112; 1990.
Frankie Ann Holmes, et al.; J. Natl. Cancer Inst.; vol. 83; No. 24; pp. 1797-1805, 1991.
Annette Bicher, et al.; Anti-Cancer Drugs; vol. 4; pp. 141-148; 1993.
Johannes J. Voegel, et al.; Helvetica Chimica Acta; vol. 76; pp. 2066-2069; 1993.
Elise C. Kohn, et al.; Journal of the National Cancer Institute; vol. 86; No. 1; pp. 18-24; 1994.
Robert A. Holton, et al.; J. Am. Chem. Soc.; vol. 116; No. 4; pp. 1597-1600; 1994.
Ernest Hamel; Med. Res. Rev.; vol. 16; pp. 207-231; 1996.
Sridhar K. Rabindran, et al.; Cancer Res.; vol. 58; pp. 5850-5858; 1998.
Carolyn M. Discafani, et al.; Biochemical Pharmacology; vol. 57; pp. 917-925; 1999.
Chun Li, et al.; Science & Medicine; vol. Jan./Feb.; pp. 38-47; 1999.
Eric K. Rowinsky and Anthony W. Tolcher; Cancer Principles and Practice; pp. 431-452; 2001.
Michael M. Gottesman; Annu. Rev. Med.; vol. 53; pp. 615-627; 2002.
Michael M. Gottesman, et al.; Nature Rev. Cancer; vol. 2; pp. 48-58; 2002.
Frank Loganzo, et al.; Cancer Res.; vol. 63; pp. 1838-1845; 2003.
P. Ribaud, European Journal of Cancer, vol. 33, Supp. 4, pp. S50-S54, 1997.
PCT International Search Report, Date of Mailing Jan. 27, 2005.

Affiliated with

Also associated with

Rating

6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3900740